Zimmer Partners’s Faeth Therapeutics FTH Stock Holding History

Zimmer Partners’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,300	Closed	-$449K	–	186
2021 Q2	$449K	Hold	2,300	–	–	0.01%	160
2021 Q1	$668K	Buy	+2,300	New	+$770K	0.01%	149

Other funds holding FTH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Zimmer Partners's FTH Position: Q3 2021 in Review

Zimmer Partners sold out of Faeth Therapeutics (FTH) in Q3 2021, closing a stake of 2,300 shares — an estimated $449K sold.

Zimmer Partners first reported a position in FTH in Q1 2021 and held it in 2 quarters. The position peaked at $668K in Q1 2021. 42 funds tracked by Wall St. Rank hold FTH as of Q3 2021.

Zimmer Partners reported no remaining Faeth Therapeutics position as of Q3 2021 after selling out during the quarter.
Zimmer Partners sold 2,300 Faeth Therapeutics shares in Q3 2021, an estimated $449K.
Zimmer Partners first reported a position in Faeth Therapeutics in Q1 2021 and held it in 2 quarters.
Zimmer Partners's Faeth Therapeutics position peaked at $668K in Q1 2021.
42 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2021.

Based on Zimmer Partners's 13F filing for Q3 2021, filed 15 Nov 2021.